Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of the study will be to demonstrate that Tobrineb/Actitob®/ Bramitob® is noninferior to TOBI® in primary efficacy variable forced expiratory volume in one second (FEV1) percent predicted in patients with CF and chronic infection of the lungs with P. aeruginosa.
Inclusion criteria
- cystic fibrosis and P. aeruginosa chronic infection